Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?

Orphanet Journal of Rare Diseases

Volumn 6, Issue 1, 2011, Pages

  Brabers, Anne Em ^a   Moors, Ellen Hm ^b   Van Weely, Sonja ^c   La De Vrueh, Remco ^c  

^a NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Dutch Steering Committee on Orphan Drugs   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ARTICLE; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; EUROPE; ONSET AGE; PREVALENCE; RARE DISEASE; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG MANUFACTURE; ECONOMICS; HUMAN; LEGAL ASPECT; METHODOLOGY; STATISTICS;

DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; EUROPE; HUMANS; ORPHAN DRUG PRODUCTION; PREVALENCE; RARE DISEASES;

EID: 80052594077     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-6-59     Document Type: Article

References (41)

1. Dear JW, Lilitkarntakul P, Webb DJ: Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Br J Clin Pharmacol 2006, 62:264-271 (Pubitemid 44215525)
2. Stolk P, Willemen MJ, Leufkens HG: Rare essentials: drugs for rare diseases as essential medicines. Bull World Health Organ 2006, 84(9):745-751 (Pubitemid 44482401)
3. Schieppati A, Henter JI, Daina E, Aperia A: Why rare diseases are an important medical and social issue. Lancet 2008, 371(9629):2039-2041 (Pubitemid 351799861)
4. The Orphan Drug Act. United States Public Law No 97-414 [http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ OrphanDrugAct/default.htm]
5. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products [http://eurlex. europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF]
6. European Commission Register of designated Orphan Medicinal Products [http://ec.europa.eu/health/documents/community-register/html/orphreg.htm]
7. The Committee for Orphan Medicinal Products and the European Medicines Agency Scientific Secretariat: European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov 2011, 10(5):341-349
8. Haffner ME: Adopting orphan drugs - two dozen years of treating rare diseases. N Engl J Med 2006, 354:445-447 (Pubitemid 43200295)
9. Haffner ME, Torrent-Farnell J, Maher PD: Does orphan drug legislation really answer the needs of patients? Lancet 2008, 371:2041-2044 (Pubitemid 351818196)
10. Rinaldi A: Adopting an orphan. EMBO Rep 2005, 6:507-510 (Pubitemid 40973956)
11. Committee for Orphan Medicinal Products report to the Commission in relation to article 10 of Regulation 141/2000 on orphan medicinal products [http://www.ema.europa.eu/docs/en-GB/document-library/Report/2010/04/ WC500089638.pdf]
12. Joppi R, Bertele V, Garattini S: Orphan drug development is not taking off. Br J Clin Pharmacol 2009, 67(5):494-502
13. Joppi R, Bertele V, Garattini S: Orphan drug development is progressing too slowly. Br J Clin Pharmacol 2006, 61(3):355-360 (Pubitemid 43382638)
14. Meyers A, Lipucci Di Paola M: The orphan medicinal products: an international challenge. Minerva Biotecnol 2003, 15:161-166 (Pubitemid 37369478)
15. Commission staff working document on the experience acquired as a result of the application of Regulation (EC) No. 141/2000 on orphan medicinal products and account of the public health benefits obtained [http://ec.europa.eu/health/ files/orphanmp/doc/orphan-en-06-2006-en.pdf]
16. Roos JC, Hyry HI, Cox TM: Orphan drug pricing may warrant a competition law investigation. BMJ 2010, 16:341
17. Tambuyzer E: Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2010, 9(12):921-929
18. Commission Regulation (EC) No. 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts 'similar medicinal product' and 'clinical superiority' [http://ec.europa.eu/health/files/ eudralex/vol-1/reg-2000-847/reg-2000-847-en.pdf]
19. Committee for Orphan Medicinal Products. Guideline on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation [http://www.emea.europa.eu/docs/en-GB/document- library/Regulatory-and-procedural-guideline/2010/07/WC500095341.pdf]
20. Heemstra HE, van Weely S, Büller HA, Leufkens HGM, de Vrueh RL: Translation of rare disease research into orphan drug development: disease matters. Drug Discov Today 2009, 14(23-24):1166-1173
21. Heemstra HE, de Vrueh RL, van Weely S, Büller HA, Leufkens HG: Predictors of orphan drug approval in the European Union. Eur J Clin Pharmacol 2008, 64(5):545-552
22. Progen. Progen and Avexa agree to withdraw from merger [http://www.progen.com.au/Docs/prs/Progen%20withdraws%20from%20Avexa%20Merger. pdf]
23. Yin W: Market incentives and pharmaceutical innovation. J Health Econ 2008, 27(4):1060-1077
24. Acemoglu D, Linn J: Market size in innovation: theory and evidence from the pharmaceutical industry. NBER Working Papers 10038 National Bureau of Economics Research 2003, 1-67
25. Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, Nguyen T, Paulus K, Merkel PA: Clinial research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009, 96(1):20-26
26. Rose K: Better medicines for children - where are we now, and where do we want to be? Br J Clin Pharmacol 2005, 59(6):657-659 (Pubitemid 40835496)
27. Saint Raymond A, Brasseur D: Development of medicines for children in Europe: ethical implications. Paediatr Respir Rev 2005, 6(1):45-51 (Pubitemid 40220869)
28. Regulation (EC) No. 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 [http://ec.europa.eu/health/files/ eudralex/vol-1/reg-2006-1901/reg-2006-1901-en.pdf]
29. Rocchi F, Paolucci P, Ceci A, Rossi P: The European paediatric legislation: benefits and perspectives. Ital J Pediatr 2010, 36:56
30. Wästfelt M, Fadeel B, Henter JI: A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med 2006, 260(1):1-10 (Pubitemid 43894064)
31. Eckhouse S, Lewison G, Sullivan R: Investments and outputs of cancer research: from the public sector to industry [http://www.ecancermedicalscience. com/cache/pdf/ECRM%20LR%20Survey.pdf]
32. Eckhouse S, Sullivan R: A survey of public funding of cancer research in the European union. PLoS Med 2006, 3(7):e267
33. Schmid EF, Smith DA: Keynote review: Is declining innovation in the pharmaceutical industry a myth? Drug Discov Today 2005, 10(15):1031-1039 (Pubitemid 41074141)
34. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature 2009. 458:719-724
35. Bonaccorsi A: Search regimes and the industrial dynamics of science. Minerva 2008, 46(3):285-315
36. DiMasi JA: Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 2001, 69(5):2997-307
37. Torrent-Farnell, J: Five years with the Orphan Drug Directive in the EU. Achievements by the COMP [http://icord.se/past-events/Stockholm-2005/speakers- presentations]
38. Heemstra HE, Giezen TJ, Mantel-Teeuwisse AK, de Vrueh RL, Leufkens HG: Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study. Drug Saf 2010, 33(2):127-137
39. European Medicines Agency: Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury [http://www.ema.europa.eu/ema/index. jsp?curl=pages/news-and-events/news/2010/12/news-detail-001161. jsp&murl=menus/news-and-events/news-and-events.jsp&mid= WC0b01ac058004d5c1&jsenabled=true]
40. Boon WPC, Moors EHM, Kuhlmann S, Smits REHM: Demand articulation in intermediary organisations: the case of orphan drugs in the Netherlands. Technological Forecasting and Social Change 2008, 75(5):644-671 (Pubitemid 351737229)
41. Aymé S, Kole A, Groft S: Empowerment of patients: lessons from the rare diseases community. Lancet 2008, 371(9629):2048-2051 (Pubitemid 351802281)